Quantitative XXXX analysis may be used to guide peripheral blood stem cell harvests.

@entity1 @entity0 @entity882 @entity1261 @entity786 @entity1398 @entity1583 @entity2280
The duration of @entity1398 and @entity882 after high-dose chemotherapy has improved since the introduction of myeloid growth factors and peripheral blood progenitor cells (PBPC), yet there remains a subset of @entity1 who have delayed @entity1583 recovery. Currently, there ar no established, reliable parameters which may be used to guide stem cell harvests. We investigated the utility of measuring harvested @entity2280 positive cell populations by flow cytometry. From March 1990 to July 1993, 30 @entity1 with @entity0 underwent therapy with high-dose @entity786 and thiotepa and stem cell rescue. @entity1 received either @entity786 (CY) mobilized PBPC or CY/ @entity1261 mobilized PBPC. The number of harvested @entity2280 + cell and CFU-GM (colony forming units-granulocyte macrophage) were quantitated for each stem cell produce. There ar complete @entity2280 data for 21 @entity1 and complete CFU-GM data for 20 @entity1 . There was a significantly delayed neutrophil recovery in those @entity1 reinfused with < 0.75 x 10(6) @entity2280 + cells/kg body weight (median days 22) compared with @entity1 reinfused with > 0.75 x 10(6)/kg (median days 12, P = 0.0004); a similar trend was seen with platelet recovery (median 135 days vs 18 days, respectively, P = 0.002). With neutrophil recovery, there was no improvement in time to engraftment with a large number of reinfused @entity2280 + cells, but there was a trend towards shortened platelet recovery when the number of reinfused @entity2280 + cells exceeded 2.0 x 10(6)/kg (median 15 days) compared with @entity2280 + < 2.0 x 10(6)/kg (median 75 days, P = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
